An open-label, randomized, multicenter, phase 3 study of trastuzumab deruxtecan with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy in HER2-expressing ovarian cancer: DESTINY-ovarian01

International Journal of Gynecological Cancer 2026

View at publisher
Authors: Antonio González-Martı́n, Kosei Hasegawa, Jo Marie Tran Janco, Jung-Yun Lee, Joyce F. Liu, Domenica Lorusso, Sven Mahner, Kathleen N. Moore, Veronica Mariotti, Joji Hara, Steven Ye Hua, David S.P. Tan
DOI: 10.1016/j.ijgc.2025.103198
Cited by: 0

Fields of Study & Subjects

Ovarian cancer diagnosis and treatment HER2/EGFR in Cancer Research PARP inhibition in cancer therapy

Publication details

Journal / source
International Journal of Gynecological Cancer
Volume
36
Issue
2
Pages
103198–103198
Publication date
1 February 2026
Language
EN